Profile data is unavailable for this security.
About the company
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
- Revenue in USD (TTM)712.89m
- Net income in USD166.52m
- Incorporated2004
- Employees1.76k
- LocationAmphastar Pharmaceuticals Inc11570 6th StRANCHO CUCAMONGA 91730United StatesUSA
- Phone+1 (909) 980-9484
- Fax+1 (302) 655-5049
- Websitehttps://amphastar.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tilray Brands Inc | 788.94m | -244.98m | 1.44bn | 2.65k | -- | 0.3987 | -- | 1.83 | -0.3334 | -0.3334 | 1.06 | 4.14 | 0.185 | 2.50 | 8.40 | 297,714.00 | -5.22 | -- | -5.72 | -- | 28.31 | -- | -28.19 | -- | 1.42 | -0.9071 | 0.0963 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
| Ocular Therapeutix Inc | 61.10m | -138.36m | 1.48bn | 267.00 | -- | 3.91 | -- | 24.19 | -1.09 | -1.09 | 0.5249 | 2.43 | 0.191 | 2.36 | 2.12 | 228,827.70 | -43.26 | -46.70 | -47.93 | -54.18 | 90.84 | 89.36 | -226.46 | -228.65 | 16.55 | -11.30 | 0.1509 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Immunocore Holdings PLC - ADR | 281.45m | -53.44m | 1.54bn | 497.00 | -- | -- | -- | 5.46 | -1.07 | -1.07 | 5.55 | -- | 0.3556 | 0.5679 | 5.56 | 566,303.60 | -6.75 | -27.55 | -8.35 | -36.82 | 99.41 | -- | -18.99 | -97.12 | 5.15 | -- | 0.5495 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Supernus Pharmaceuticals Inc | 630.16m | 5.24m | 1.77bn | 652.00 | 362.96 | 1.84 | 19.58 | 2.80 | 0.0883 | 0.0883 | 11.39 | 17.39 | 0.4831 | 0.9256 | 4.36 | 966,507.70 | 0.4016 | 4.95 | 0.5117 | 6.41 | 88.34 | 88.61 | 0.8314 | 12.84 | 1.69 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Harrow Inc | 154.15m | -33.58m | 1.80bn | 315.00 | -- | 30.70 | -- | 11.66 | -0.9508 | -0.9508 | 4.38 | 1.65 | 0.581 | 4.95 | 4.39 | 489,352.40 | -12.66 | -10.86 | -14.77 | -12.71 | 71.16 | 70.75 | -21.78 | -15.35 | 2.43 | -0.3518 | 0.7608 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Endo Inc | -100.00bn | -100.00bn | 1.87bn | 3.00k | -- | 1.02 | -- | -- | -- | -- | -- | 23.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.52 | -- | 0.5697 | -- | -13.25 | -- | 15.87 | -- | -- | -- |
| Ligand Pharmaceuticals Inc | 133.48m | 42.14m | 1.87bn | 58.00 | 46.12 | 2.40 | 24.26 | 14.05 | 2.22 | 2.22 | 7.33 | 42.82 | 0.1643 | 0.4789 | 4.08 | 2,301,345.00 | 5.19 | 12.32 | 5.35 | 12.99 | 91.82 | 81.65 | 31.57 | 80.32 | 15.81 | -- | 0.00002 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Harmony Biosciences Holdings Inc | 656.11m | 114.99m | 1.95bn | 246.00 | 17.60 | 3.63 | 14.02 | 2.98 | 1.95 | 1.95 | 11.19 | 9.48 | 0.8107 | 25.74 | 8.93 | 2,667,110.00 | 14.21 | 7.46 | 16.68 | 9.08 | 79.41 | 80.58 | 17.53 | 10.46 | 3.09 | 52.20 | 0.2571 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Vericel Corp | 214.52m | 789.00k | 2.01bn | 314.00 | 2,171.34 | 8.26 | 339.03 | 9.38 | 0.0189 | 0.0189 | 4.46 | 4.97 | 0.624 | 4.41 | 4.97 | 683,184.70 | 0.2295 | -3.07 | 0.2595 | -3.50 | 70.42 | 67.87 | 0.3678 | -4.49 | 4.16 | -- | 0.0008 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Amphastar Pharmaceuticals Inc | 712.89m | 166.52m | 2.28bn | 1.76k | 14.92 | 3.21 | 10.38 | 3.20 | 3.14 | 3.14 | 13.45 | 14.57 | 0.4968 | 2.85 | 6.04 | 404,821.70 | 11.71 | 9.42 | 13.54 | 11.56 | 54.68 | 47.83 | 23.56 | 15.23 | 2.63 | 7.42 | 0.4515 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Catalyst Pharmaceuticals Inc | 434.48m | 68.15m | 2.34bn | 167.00 | 36.98 | 3.84 | 22.36 | 5.39 | 0.5335 | 0.5335 | 3.71 | 5.14 | 0.7554 | 4.03 | 8.69 | 2,601,647.00 | 11.85 | 25.42 | 13.56 | 29.81 | 86.67 | 85.63 | 15.69 | 30.87 | 4.94 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Twist Bioscience Corp | 295.21m | -220.31m | 2.47bn | 919.00 | -- | 5.02 | -- | 8.36 | -3.81 | -3.81 | 5.12 | 8.39 | 0.4076 | 5.42 | 8.56 | 321,229.60 | -30.42 | -30.50 | -33.85 | -33.84 | 40.53 | 36.02 | -74.63 | -113.33 | 4.52 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| Amneal Pharmaceuticals Inc | 2.60bn | -174.62m | 2.62bn | 7.70k | -- | -- | 28.45 | 1.01 | -0.6224 | -0.6224 | 10.09 | -0.1857 | 0.7206 | 3.00 | 3.60 | 337,401.60 | -3.69 | -4.80 | -4.93 | -5.93 | 35.04 | 34.76 | -5.13 | -9.00 | 0.8165 | 1.24 | 1.00 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
Data as of Oct 08 2024. Currency figures normalised to Amphastar Pharmaceuticals Inc's reporting currency: US Dollar USD
38.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 5.57m | 11.39% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.62m | 5.36% |
| Federated Global Investment Management Corp.as of 30 Jun 2024 | 1.94m | 3.97% |
| TD Asset Management, Inc.as of 30 Jun 2024 | 1.69m | 3.46% |
| Neuberger Berman Investment Advisers LLCas of 31 Mar 2024 | 1.66m | 3.39% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.51m | 3.10% |
| Fuller & Thaler Asset Management, Inc.as of 30 Jun 2024 | 1.27m | 2.60% |
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 1.05m | 2.14% |
| Geode Capital Management LLCas of 30 Jun 2024 | 906.35k | 1.85% |
| Epoch Investment Partners, Inc.as of 31 Mar 2024 | 798.46k | 1.63% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
